Drug Type Recombinant protein |
Synonyms Ad-ISF35 transduced CLL B-cells, Immune Stimulatory Factor 35, AD-CD154 + [4] |
Target |
Mechanism CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Melanoma | Phase 2 | - | 01 Mar 2018 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | US | 01 Jun 2009 | |
Follicular Lymphoma | Phase 2 | US | 01 Jun 2009 | |
Mantle-Cell Lymphoma | Phase 2 | US | 01 Jun 2009 | |
Chronic Lymphocytic Leukemia | Phase 2 | US | 01 Jan 2009 | |
Small Lymphocytic Lymphoma | Phase 2 | US | 01 Jan 2009 |
Phase 2 | 5 | dowceustog(qqtgnzsrdl) = djexiaazei sjekthhmuv (qnezeghzyq, hwswvrgsnl - datnsrtqdd) View more | - | 20 Nov 2015 | |||
Phase 2 | 6 | qksfbhcrby(krmdxyjtdq) = fqiydpgkqp cchomvyjmq (kepklffyia, ojopineenh - rrcgkdhfng) View more | - | 20 Nov 2015 |